An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
Chronic Schizophrenia
About this trial
This is an interventional treatment trial for Chronic Schizophrenia
Eligibility Criteria
Inclusion Criteria: Fulfills DSM-IV criteria for schizophrenia. Unable to achieve competitive employment status within the past five years. Unable to live independently in the community. Maintained on a stable regimen of antipsychotic medication for at least two weeks prior to enrollment. Exclusion Criteria: History of significant hepatic, renal, pulmonary, endocrine, active peptic ulcer disease or cardiovascular disease. History of seizure disorder and/or head injury. Co-morbid substance use/abuse disorder. Received an investigational medication within the previous month. Due to the risk of adverse effects on fetal development: women with any risk of becoming pregnant will be excluded from this study.
Sites / Locations
- Maryland Psychiatric Research Center